Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

(Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent ...

A man suffering a condition so excruciatingly painful it's dubbed 'suicide disease' left doctors baffled for four years - ...

In a new study, numerous genomic regions potentially affecting the structure of the discs and inflammatory factors were found ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior year period. The increase in research and development expense was primarily ...

Topline results are anticipated in Q4 2025 and, assuming positive data, Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. QUTENZA (capsaicin) 8% topical system is ...

However, not long after settling in Perth, the pain she had been experiencing for years on the right side of her face returned. The sensation, which Gracie likened to someone 'smashing a screwdriver ...

Hereditary risk factors for disc herniations were investigated in a study led by a University of Oulu research group, utilising data from FinnGen, the Estonian Biobank, and the UK Biobank. The study ...

Pain-sensing neurons exchange signals with immune cells that drive endometriosis, sparking the pain associated with the condition, new research suggests.